Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06376851 · ClinicalTrials.gov registry record
AI DErived Plaque Quantification: CCTA and AI-QCPA for Determining Effective CAD Management
A clinical trial of Coronary Artery Disease, sponsored by HeartFlow.
- Active
- Registry status
- 20,000
- Enrollment target
- 1
- Study location
NCT06376851: Active study of Coronary Artery Disease, sponsored by HeartFlow.
NCT06376851 is a study of Coronary Artery Disease that is active but no longer recruiting, run by HeartFlow. The registered enrollment target is 20,000 participants, above the 1,196-participant average among 219 other Coronary Artery Disease trials with a reported enrollment target (1572% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06376851, a study of Coronary Artery Disease, is active but no longer recruiting, sponsored by HeartFlow.
- ACTIVE NOT RECRUITING
- Registry status
- 20,000 participants
- Enrollment target
- 1
- Study location
Study Summary
The objective of HeartFlow's DECIDE Registry is to collect observational data about the management of patients before and after HeartFlow Artificial Intelligence-Quantitative Coronary Plaque Analysis (AI-QCPA).
Primary Outcome
The primary endpoint of the DECIDE Registry is the change in medical management following HeartFlow AI-QCPA at 90 days compared to medical management following CCTA alone. The primary endpoint will only be assessed in patients in Group 2.
Conditions Studied
Interventions
- DIAGNOSTIC_TEST AI-enabled quantitative coronary plaque analysis (AI-QCPA)
Study Locations (1)
North Carolina
- Moses Cone Memorial Hospital - Greensboro
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20,000 participants |
| Start Date | 2024-03-27 |
| Est. Completion | 2030-03-27 |
What the registry record for NCT06376851 still lists
NCT06376851 is an observational study that tracks outcomes without assigning an intervention. Its 20,000 participants enrollment target places it among the larger protocols in the corpus, above the 1,196-participant average among 219 other Coronary Artery Disease trials with a reported enrollment target (1572% higher).
The record links to 1 condition, with Coronary Artery Disease appearing as the primary indexed condition, and to 1 intervention - of which AI-enabled quantitative coronary plaque analysis (AI-QCPA) is the first listed.
NCT06376851 reports a single indexed study location in North Carolina.
Frequently Asked Questions
What is clinical trial NCT06376851 about?
NCT06376851 is a clinical study titled "AI DErived Plaque Quantification: CCTA and AI-QCPA for Determining Effective CAD Management". The objective of HeartFlow's DECIDE Registry is to collect observational data about the management of patients before and after HeartFlow Artificial Intelligence-Quantitative Coronary Plaque Analysis (AI-QCPA).
What is the current status of trial NCT06376851?
This trial is currently active not recruiting. The enrollment target is 20,000 participants. The study started on 2024-03-27. Estimated completion is 2030-03-27.
What conditions does trial NCT06376851 study?
This clinical trial studies the following conditions: Coronary Artery Disease.
What interventions are being tested in trial NCT06376851?
The interventions under investigation include: AI-enabled quantitative coronary plaque analysis (AI-QCPA) (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT06376851?
This trial is sponsored by HeartFlow, which has 8 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06376851 being conducted?
This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Coronary Artery Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06376851's enrollment target sits among peer trials
20,000 3rd of 219 higher than 217 of 219 other Coronary Artery Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Coronary Artery Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
MCNAIR Study: coMparative effeCtiveness of iN-person and teleheAlth cardIac Rehabilitation
RECRUITING · NA
-
MagicTouch for Treatment of In-Stent Restenosis in Coronary Artery Lesions
RECRUITING · NA
-
PET/CT* vs. Cardiac CT for Detecting Coronary Atherosclerotic Disease [*PET: Positron Emission Tomography; CT: Computed Tomography]
RECRUITING · NA
-
Factors Affect Outcomes in Cardiovascular Surgery
RECRUITING
-
Polygenic Risk-based Detection of Subclinical Coronary Atherosclerosis and Change in Cardiovascular Health
RECRUITING · NA
-
Impact of Disclosing Coronary Artery Disease Polygenic Risk Score on Cardiovascular Health
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00271180 · 20,000 participants
Product Performance Report: Evaluate Long-term Reliability & Performance of Medtronic Marketed Cardiac Therapy Products
- NCT00830557 · 20,000 participants
Collecting Medical Information and Tissue Samples From Patients With Pancreatic Cancer or Other Pancreatic Disorders
- NCT00900471 · 20,000 participants
Collection and Storage of Tissue Samples From Patients Undergoing Surgery For Suspected Solid Tumors
- NCT02735707 · 20,000 participants · Phase 3
Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI